Scalper1 News
Big biotech Regeneron Pharmaceuticals (REGN) was down nearly 5% Wednesday as Wall Street digested the impact of an ambiguous FDA advisory committee vote on its cholesterol drug Praluent late Tuesday. Meanwhile, rival Amgen (AMGN) was off 2% as the committee reconvened to vote on its similar drug Repatha. The panel endorsed approval overall, but the caution around the real connection between lower LDL cholesterol and cardiovascular health raised Scalper1 News
Scalper1 News